Novo Nordisk shares have dropped ~50% since June 2024 due to poor trial results and other negative catalysts. See why I rate ...

Novo Holdings, the controlling shareholder of weight loss drugmaker Novo Nordisk A/S (NYSE:NVO), reported Wednesday income and investment returns of 60 billion Danish kroner (around $8.68 billion) for ...

Artisan Partners, an investment management company, released its “Artisan Global Opportunities Fund” fourth quarter 2024 ...

Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results. Read why I rate NVO stock a strong buy right now.

Bagsværd: Novo Nordisk HA has announced that Camilla Sylvest has decided to leave the company after a distinguished career of ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, ...

We recently published a list of 10 Best Beaten Down Stocks to Buy According to Analysts. In this article, we are going to ...

As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued ...

Both CagriSema and retatrutide are set to seek regulatory approval in the first quarter of 2026. Price cuts in the most popular weight-loss drug Despite recent setbacks, Novo Nordisk’s latest ...

Danish drugmaker Novo Nordisk has been dethroned by German software giant SAP as Europe’s most valuable company. SAP has ...

Novo Nordisk’s stock price has fallen almost ... the company announced phase 3 trial results for its cocktail obesity drug, CagriSema. Results showed a weight loss of 22.7% after 68 weeks ...

A series of disappointing trial results for Novo Nordisk’s next-generation weight-loss drugs has exacerbated investor concerns about its competitiveness. In December 2024, the company announced phase ...